Photo taken from AACR/Twitter
Oct 18, 2023, 16:43
U.S. FDA approved pembrolizumab for NSCLC as single-agent for adjuvant and in combination with chemo for neoadjuvant settings – American Association for Cancer Research
American Association for Cancer Research recently shared on its Twitter page:
“Today, the U.S. FDA approved the immune checkpoint inhibitor pembrolizumab in combination with chemotherapy before surgery and continuation as a single-agent treatment after surgery for some patients with non-small cell lung cancer.”
Source: AACR/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38